[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100646791":3},{"organization":4,"armGroups":7,"interventions":22,"overallOfficials":27,"centralContacts":36,"locations":42,"responsibleParty":56,"collaborators":27,"id":58,"slug":59,"hasResults":60,"nctId":61,"briefTitle":62,"officialTitle":63,"acronym":27,"eligibilityCriteria":64,"healthyVolunteers":60,"sex":65,"minAge":66,"maxAge":67,"enrollmentInfo":68,"targetDuration":27,"studyType":71,"phases":72,"briefSummary":74,"conditions":75,"keywords":27,"overallStatus":45,"whyStopped":27,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":81,"completionDateStruct":82,"leadSponsor":84,"locationsCount":85},{"fullName":5,"class":6},"Dong-A ST Co., Ltd.","INDUSTRY",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"DA-9701","EXPERIMENTAL","administered for 4weeks(DA-9701 + DA-9701-R placebo)",[13,14],"Drug: DA-9701","Drug: DA-9701-R Placebo",{"label":16,"type":17,"description":18,"interventionNames":19},"DA-9701-R","ACTIVE_COMPARATOR","administered for 4weeks(DA-9701-R + DA-9701 placebo)",[20,21],"Drug: DA-9701-R","Drug: DA-9701 Placebo",[23,28,30,33],{"type":24,"name":9,"description":25,"armGroupLabels":26,"otherNames":27},"DRUG","1 tablet, TID",[9],null,{"type":24,"name":16,"description":25,"armGroupLabels":29,"otherNames":27},[16],{"type":24,"name":31,"description":25,"armGroupLabels":32,"otherNames":27},"DA-9701 Placebo",[16],{"type":24,"name":34,"description":25,"armGroupLabels":35,"otherNames":27},"DA-9701-R Placebo",[9],[37],{"name":38,"role":39,"phone":40,"phoneExt":27,"email":41},"Sang Kil Lee","CONTACT","+82) 02-2228-4000","SKLEE@yuhs.ac",[43],{"facility":44,"status":45,"city":46,"state":27,"zip":27,"country":47,"countryCode":27,"cosmosGeoPoint":48,"geoPoint":53,"contacts":54},"Severance Hospital","RECRUITING","Seoul","South Korea",{"type":49,"coordinates":50},"Point",[51,52],126.9784,37.566,{"lat":52,"lon":51},[55],{"name":38,"role":39,"phone":40,"phoneExt":27,"email":41},{"type":57,"investigatorFullName":27,"investigatorTitle":27,"investigatorAffiliation":27,"oldNameTitle":27,"oldOrganization":27},"SPONSOR","100646791","a-study-to-evaluate-the-efficacy-and-safety-of-da-9701-in-patients-with-functional-dyspepsia-100646791",false,"NCT07686679","A Study to Evaluate the Efficacy and Safety of DA-9701 in Patients With Functional Dyspepsia","A Multicenter, Double-blind, Active-controlled, Randomized, Parallel, Phase IV Clinical Trial to Evaluate the Efficacy and Safety of DA-9701 in Patients With Functional Dyspepsia","Main Inclusion Criteria:\n\n* Men or women aged 19 to 75 years, inclusive\n* Subjects diagnosed with functional dyspepsia according to the Rome IV criteria\n* Subjects with at least three symptoms rated as moderate or severe on the Gastrointestinal Symptom Score(GIS)\n* Subjects who voluntarily signed a consent form\n\nMain Exclusion Criteria:\n\n* Subjects with a history of organic diseases that could cause dyspepsia\n* Subjects with hypersensitivity to investigational drugs and similar drugs\n* Pregnant or breastfeeding women","ALL","19 Years","75 Years",{"count":69,"type":70},300,"ESTIMATED","INTERVENTIONAL",[73],"PHASE4","This study will evaluate the efficacy and safety of DA-9701 in patients with functional dyspepsia",[76],"Functional Dyspepsia","2026-08-06",{"date":79,"type":80},"2026-08-10","ACTUAL",{"date":77,"type":80},{"date":83,"type":70},"2027-10",{"name":5,"class":6},1]